SCHEMBL7003843

SCHEMBL7003843

CC(C)(C)OC(=O)NC1Cc2ccccc2N(C(=O)OC(C)(C)C)C1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 1/20 0.54
DRD2 P14416 4/20 0.46
PIM1 P11309 1/20 0.45
PIM3 Q86V86 1/20 0.45
PIM2 Q9P1W9 1/20 0.45
KMT2A Q03164 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
MTNR1A P48039 2/20 0.44
MTNR1B P49286 2/20 0.44
KDM1A O60341 2/20 0.43
NAMPT P43490 2/20 0.43
MAOB P27338 1/20 0.43
REN P00797 1/20 0.41
KCNA3 P22001 1/20 0.40
DRD3 P35462 1/20 0.40
BCHE P06276 1/20 0.40
PDE10A Q9Y233 1/20 0.40
CKS1B P61024 1/20 0.40
SKP1 P63208 1/20 0.40
SKP2 Q13309 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8564090 0.94 EPHX2 (0.47) EPHX2DRD2PIM1PIM3PIM2
SCHEMBL8566397 0.94 EPHX2 (0.47) EPHX2DRD2PIM1PIM3PIM2
SCHEMBL8564093 0.94 EPHX2 (0.47) EPHX2DRD2PIM1PIM3PIM2
SCHEMBL12679645 0.90 EPHX2 (0.54) EPHX2DRD2PIM1PIM3PIM2
SCHEMBL7006038 0.90 EPHX2 (0.54) EPHX2DRD2PIM1PIM3PIM2
SCHEMBL2489959 0.87 EPHX2 (0.51) EPHX2DRD2PIM1PIM3PIM2
SCHEMBL27057854 0.84 EPHX2 (0.51) EPHX2DRD2PIM1PIM3PIM2
SCHEMBL14175284 0.84 EPHX2 (0.55) EPHX2DRD2PIM1PIM3PIM2
SCHEMBL2517874 0.81 MTNR1A (0.67) EPHX2DRD2PIM1PIM3PIM2
SCHEMBL30576518 0.81 MTNR1A (0.67) EPHX2DRD2PIM1PIM3PIM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030105118-A1 Tricyclic quinazolinediones SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2003-06-05 US disclosed
EP-1288216-A1 TRICYCLIC QUINAZOLINEDIONES SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2003-03-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030105118-A1 Tricyclic quinazolinediones PARP1, PARP11, PARP2 EPHX2 3431/4885DRD2 1008/4885PIM1 3901/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.